Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with bundibugyo ebolavirus

Darryl Falzarano, Friederike Feldmann, Allen Grolla, Anders Leung, Hideki Ebihara, James E. Strong, Andrea Marzi, Ayato Takada, Shane Jones, Jason Gren, Joan Geisbert, Steven M. Jones, Thomas Geisbert, Heinz Feldmann

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a filovirus glycoprotein has been demonstrated to provide protection from lethal challenge with Ebola (EBOV) and Marburg (MARV) viruses both prophylactically and after exposure. This platform provides protection between heterologous strains within a species; however, protection from lethal challenge between species has been largely unsuccessful. To determine whether the rVSV-EBOV vaccines have the potential to provide protection against a newly emerging, phylogenetically related species, cynomolgus macaques were vaccinated with an rVSV vaccine expressing either the glycoprotein of Zaire ebolavirus (ZEBOV) or Côte d'Ivoire ebolavirus (CIEBOV) and then challenged with Bundibugyo ebolavirus (BEBOV), which was recently proposed as a new EBOV species following an outbreak in Uganda in 2007. A single vaccination with the ZEBOV-specific vaccine provided cross-protection (75% survival) against subsequent BEBOV challenge, whereas vaccination with the CIEBOV-specific vaccine resulted in an outcome similar to mock-immunized animals (33% and 25% survival, respectively). This demonstrates that monovalent rVSV-based vaccines may be useful against a newly emerging species; however, heterologous protection across species remains challenging and may depend on enhancing the immune responses either through booster immunizations or through the inclusion of multiple immunogens.

Original languageEnglish (US)
JournalJournal of Infectious Diseases
Volume204
Issue numberSUPPL. 3
DOIs
StatePublished - Nov 1 2011

Fingerprint

Ebolavirus
Vesicular Stomatitis
Primates
Immunization
Vaccines
Viruses
Democratic Republic of the Congo
Glycoproteins
Vaccination
Marburgvirus
Cross Protection
Secondary Immunization
Uganda
Macaca
Disease Outbreaks

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with bundibugyo ebolavirus. / Falzarano, Darryl; Feldmann, Friederike; Grolla, Allen; Leung, Anders; Ebihara, Hideki; Strong, James E.; Marzi, Andrea; Takada, Ayato; Jones, Shane; Gren, Jason; Geisbert, Joan; Jones, Steven M.; Geisbert, Thomas; Feldmann, Heinz.

In: Journal of Infectious Diseases, Vol. 204, No. SUPPL. 3, 01.11.2011.

Research output: Contribution to journalArticle

Falzarano, D, Feldmann, F, Grolla, A, Leung, A, Ebihara, H, Strong, JE, Marzi, A, Takada, A, Jones, S, Gren, J, Geisbert, J, Jones, SM, Geisbert, T & Feldmann, H 2011, 'Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with bundibugyo ebolavirus', Journal of Infectious Diseases, vol. 204, no. SUPPL. 3. https://doi.org/10.1093/infdis/jir350
Falzarano, Darryl ; Feldmann, Friederike ; Grolla, Allen ; Leung, Anders ; Ebihara, Hideki ; Strong, James E. ; Marzi, Andrea ; Takada, Ayato ; Jones, Shane ; Gren, Jason ; Geisbert, Joan ; Jones, Steven M. ; Geisbert, Thomas ; Feldmann, Heinz. / Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with bundibugyo ebolavirus. In: Journal of Infectious Diseases. 2011 ; Vol. 204, No. SUPPL. 3.
@article{3db403d59a684a14bdb639b44412707c,
title = "Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with bundibugyo ebolavirus",
abstract = "The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a filovirus glycoprotein has been demonstrated to provide protection from lethal challenge with Ebola (EBOV) and Marburg (MARV) viruses both prophylactically and after exposure. This platform provides protection between heterologous strains within a species; however, protection from lethal challenge between species has been largely unsuccessful. To determine whether the rVSV-EBOV vaccines have the potential to provide protection against a newly emerging, phylogenetically related species, cynomolgus macaques were vaccinated with an rVSV vaccine expressing either the glycoprotein of Zaire ebolavirus (ZEBOV) or C{\^o}te d'Ivoire ebolavirus (CIEBOV) and then challenged with Bundibugyo ebolavirus (BEBOV), which was recently proposed as a new EBOV species following an outbreak in Uganda in 2007. A single vaccination with the ZEBOV-specific vaccine provided cross-protection (75{\%} survival) against subsequent BEBOV challenge, whereas vaccination with the CIEBOV-specific vaccine resulted in an outcome similar to mock-immunized animals (33{\%} and 25{\%} survival, respectively). This demonstrates that monovalent rVSV-based vaccines may be useful against a newly emerging species; however, heterologous protection across species remains challenging and may depend on enhancing the immune responses either through booster immunizations or through the inclusion of multiple immunogens.",
author = "Darryl Falzarano and Friederike Feldmann and Allen Grolla and Anders Leung and Hideki Ebihara and Strong, {James E.} and Andrea Marzi and Ayato Takada and Shane Jones and Jason Gren and Joan Geisbert and Jones, {Steven M.} and Thomas Geisbert and Heinz Feldmann",
year = "2011",
month = "11",
day = "1",
doi = "10.1093/infdis/jir350",
language = "English (US)",
volume = "204",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with bundibugyo ebolavirus

AU - Falzarano, Darryl

AU - Feldmann, Friederike

AU - Grolla, Allen

AU - Leung, Anders

AU - Ebihara, Hideki

AU - Strong, James E.

AU - Marzi, Andrea

AU - Takada, Ayato

AU - Jones, Shane

AU - Gren, Jason

AU - Geisbert, Joan

AU - Jones, Steven M.

AU - Geisbert, Thomas

AU - Feldmann, Heinz

PY - 2011/11/1

Y1 - 2011/11/1

N2 - The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a filovirus glycoprotein has been demonstrated to provide protection from lethal challenge with Ebola (EBOV) and Marburg (MARV) viruses both prophylactically and after exposure. This platform provides protection between heterologous strains within a species; however, protection from lethal challenge between species has been largely unsuccessful. To determine whether the rVSV-EBOV vaccines have the potential to provide protection against a newly emerging, phylogenetically related species, cynomolgus macaques were vaccinated with an rVSV vaccine expressing either the glycoprotein of Zaire ebolavirus (ZEBOV) or Côte d'Ivoire ebolavirus (CIEBOV) and then challenged with Bundibugyo ebolavirus (BEBOV), which was recently proposed as a new EBOV species following an outbreak in Uganda in 2007. A single vaccination with the ZEBOV-specific vaccine provided cross-protection (75% survival) against subsequent BEBOV challenge, whereas vaccination with the CIEBOV-specific vaccine resulted in an outcome similar to mock-immunized animals (33% and 25% survival, respectively). This demonstrates that monovalent rVSV-based vaccines may be useful against a newly emerging species; however, heterologous protection across species remains challenging and may depend on enhancing the immune responses either through booster immunizations or through the inclusion of multiple immunogens.

AB - The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a filovirus glycoprotein has been demonstrated to provide protection from lethal challenge with Ebola (EBOV) and Marburg (MARV) viruses both prophylactically and after exposure. This platform provides protection between heterologous strains within a species; however, protection from lethal challenge between species has been largely unsuccessful. To determine whether the rVSV-EBOV vaccines have the potential to provide protection against a newly emerging, phylogenetically related species, cynomolgus macaques were vaccinated with an rVSV vaccine expressing either the glycoprotein of Zaire ebolavirus (ZEBOV) or Côte d'Ivoire ebolavirus (CIEBOV) and then challenged with Bundibugyo ebolavirus (BEBOV), which was recently proposed as a new EBOV species following an outbreak in Uganda in 2007. A single vaccination with the ZEBOV-specific vaccine provided cross-protection (75% survival) against subsequent BEBOV challenge, whereas vaccination with the CIEBOV-specific vaccine resulted in an outcome similar to mock-immunized animals (33% and 25% survival, respectively). This demonstrates that monovalent rVSV-based vaccines may be useful against a newly emerging species; however, heterologous protection across species remains challenging and may depend on enhancing the immune responses either through booster immunizations or through the inclusion of multiple immunogens.

UR - http://www.scopus.com/inward/record.url?scp=80054742592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054742592&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir350

DO - 10.1093/infdis/jir350

M3 - Article

VL - 204

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - SUPPL. 3

ER -